MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

11192	Companies
247568	Keywords
175394	Articles
133791	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/19/2025 at 14:30, 1 year 1 month ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
MIRA Pharmaceuticals, Inc. announces successful completion of Phase 1 Single Ascending Dose trial for oral Ketamir-2, preparing for U.S. Phase 2a trial in Q4 2025

Clinical Trial Phase 1 MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 08/12/2025 at 14:35, 1 year 2 months ago

MIRA Pharmaceuticals développe le kétamir-2 pour le traitement de la douleur neuropathique

Essais Cliniques Croissance Du Marché Médicaments Ketamir-2 Douleur Neuropathique
BRIEF

published on 08/12/2025 at 14:35, 1 year 2 months ago

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

Pharmaceuticals Clinical Trials Market Growth Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 08/12/2025 at 14:30, 1 year 2 months ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
MIRA Pharmaceuticals announces the acceptance of a manuscript in Frontiers in Pharmacology detailing Ketamir-2's efficacy in neuropathic pain, supporting Phase 2a trials by 2025

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pharmacology
BRIEF

published on 07/30/2025 at 13:35, 1 year 2 months ago

Le kétamir-2 topique de MIRA Pharmaceuticals est comparable à la morphine injectée dans une étude sur la douleur

Soulagement De La Douleur Étude Préclinique Kétamir-2 Topique Comparaison De La Morphine Traitement Localisé
BRIEF

published on 07/30/2025 at 13:35, 1 year 2 months ago

MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

Preclinical Study Pain Relief Topical Ketamir-2 Morphine Comparison Localized Treatment
PRESS RELEASE

published on 07/30/2025 at 13:30, 1 year 2 months ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
MIRA Pharmaceuticals announces new preclinical data showing topical Ketamir-2 provides effective pain relief comparable to injected morphine in animal models. The treatment has potential for both centralized and localized pain pathways

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Pain Relief
BRIEF

published on 07/29/2025 at 13:35, 1 year 2 months ago

MIRA Pharmaceuticals reçoit le feu vert de la FDA pour les essais du kétamir-2

Autorisation De La FDA Expansion Stratégique Ketamir-2 Douleur Neuropathique Essai De Phase 1
BRIEF

published on 07/29/2025 at 13:35, 1 year 2 months ago

MIRA Pharmaceuticals Receives FDA Green Light for Ketamir-2 Trials

FDA Clearance Phase 1 Trial Strategic Expansion Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 07/29/2025 at 13:30, 1 year 2 months ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
MIRA Pharmaceuticals advances non-opioid oral drug Ketamir-2 for neuropathic pain, clears FDA IND for Phase 2a, demonstrates potent effects in preclinical studies

FDA Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 10/17/2026 at 03:20, 1 day 18 hours ago

Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Published on 10/17/2026 at 03:15, 1 day 18 hours ago

Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Published on 10/16/2026 at 23:35, 1 day 22 hours ago

Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 1 day 22 hours ago

NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 1 day 22 hours ago

Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update

View all ACCESSWIRE

EQS Group

Published on 10/18/2026 at 14:05, 7 hours 50 minutes ago

UEG launches new Patient Representatives Advisory Board to strengthen patient voice in digestive health
Published on 10/17/2026 at 18:00, 1 day 3 hours ago

Baader Bank announces extended trading hours 23 hours a day starting Q1/2027
Published on 10/17/2026 at 13:05, 1 day 8 hours ago

Luong Quoi Coconut Vietnam to Showcase Vietnamese Coconut Expertise at SIAL Paris 2026
Published on 10/17/2026 at 12:50, 1 day 9 hours ago

AGFUND wins international award for excellence in inclusive banking and social impact
Published on 10/16/2026 at 20:08, 2 days 1 hour ago

EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme

Les Echos

Published on 10/16/2026 at 19:54, 2 days 2 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 30 septembre 2026
Published on 10/16/2026 at 18:48, 2 days 3 hours ago

Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/16/2026 at 18:48, 2 days 3 hours ago

Déclaration hebdomadaire d'opérations effectuées du 12 au 16 octobre 2026
Published on 10/16/2026 at 18:00, 2 days 3 hours ago

KLARSEN : Compte rendu AGO et AGE du 8 octobre 2026
Published on 10/16/2026 at 07:30, 2 days 14 hours ago

Third Quarter Revenues 2026

View all LES ECHOS COMFI WIRE